{
    "id": 2237,
    "fullName": "JAK3 A572V",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "JAK3 A572V lies within the protein kinase domain 1 of the Jak3 protein (UniProt.org). A572V confers a gain of function to the Jak3 protein, as demonstrated by increased Jak3 autophosphorylation (PMID: 29046866), constitutive phosphorylation of Jak3 and activation of downstream Stat5 (PMID: 22705984), and leads to cytokine-independent proliferation of cultured cells (PMID: 22705984, PMID: 28284718).",
            "references": [
                {
                    "id": 12536,
                    "pubMedId": 29046866,
                    "title": "Transforming Mutations of Jak3 (A573V and M511I) Show Differential Sensitivity to Selective Jak3 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29046866"
                },
                {
                    "id": 821,
                    "pubMedId": 22705984,
                    "title": "Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22705984"
                },
                {
                    "id": 12375,
                    "pubMedId": 28284718,
                    "title": "Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28284718"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 3718,
        "geneSymbol": "JAK3",
        "terms": [
            "JAK3",
            "JAK-3",
            "JAK3_HUMAN",
            "JAKL",
            "L-JAK",
            "LJAK"
        ]
    },
    "variant": "A572V",
    "createDate": "10/14/2014",
    "updateDate": "10/11/2018",
    "referenceTranscriptCoordinates": {
        "id": 93599,
        "transcript": "NM_000215",
        "gDna": "chr19:g.17837200G>A",
        "cDna": "c.1715C>T",
        "protein": "p.A572V",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10922,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human cells expressing JAK3 A572V in culture demonstrated decreased cell survival, increased G1 arrest, elevated apoptotic activity, and reduced phosphorylation of Stat5a when treated with Xeljanz (tofacitinib) (PMID: 21821710).",
            "molecularProfile": {
                "id": 2168,
                "profileName": "JAK3 A572V"
            },
            "therapy": {
                "id": 941,
                "therapyName": "Tofacitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8930,
                    "pubMedId": 21821710,
                    "title": "FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21821710"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13070,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an acute myeloid leukemia cell line harboring JAK3 A572V was insensitive to treatment with NS-108 in culture (PMID: 22829185).",
            "molecularProfile": {
                "id": 2168,
                "profileName": "JAK3 A572V"
            },
            "therapy": {
                "id": 2780,
                "therapyName": "NS-018",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 2936,
                    "pubMedId": 22829185,
                    "title": "Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22829185"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1087,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xeljanz (tofacitinib), a pan-JAK inhibitor, reduced cell viability and increased apoptosis in a JAK3 A572V mutant natural killer/T-cell lymphoma cell line (PMID: 22705984).",
            "molecularProfile": {
                "id": 2168,
                "profileName": "JAK3 A572V"
            },
            "therapy": {
                "id": 941,
                "therapyName": "Tofacitinib",
                "synonyms": null
            },
            "indication": {
                "id": 50743,
                "name": "mature T-cell and NK-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 821,
                    "pubMedId": 22705984,
                    "title": "Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22705984"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2168,
            "profileName": "JAK3 A572V",
            "profileTreatmentApproaches": [
                {
                    "id": 5178,
                    "name": "JAK Inhibitor (Pan)",
                    "profileName": "JAK3 A572V"
                },
                {
                    "id": 5180,
                    "name": "JAK3 Inhibitor",
                    "profileName": "JAK3 A572V"
                },
                {
                    "id": 5179,
                    "name": "JAK Inhibitor (Pan) - ATP competitive",
                    "profileName": "JAK3 A572V"
                },
                {
                    "id": 5181,
                    "name": "JAK3 Inhibitor - ATP competitive",
                    "profileName": "JAK3 A572V"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 93599,
            "transcript": "NM_000215",
            "gDna": "chr19:g.17837200G>A",
            "cDna": "c.1715C>T",
            "protein": "p.A572V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}